zorecimeran (CV07050101) / CureVac 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zorecimeran (CV07050101) / CureVac
2021-001735-10: COVID-19: A study to learn about the safety, local and systemic reactions, and the immune responses to the SARS-CoV-2 mRNA Vaccine (CVnCoV) when given to participants 45 years or older who have either a solid tumor or blood cancer and are already taking or about to start systemic anticancer therapy

Ongoing
3
620
Europe
CVnCoV, CV07050101, Solution for injection
Bayer AG, Bayer AG
Vaccination for prophylaxis of coronavirus disease 2019 (COVID-19), Vaccination for prevention of coronavirus disease 2019 (COVID-19), Diseases [C] - Virus Diseases [C02]
 
 
NCT04834869: COVID-19 Vaccines Safety Tracking (CoVaST)

Recruiting
N/A
30000
Europe, Canada, US, RoW
BNT162b2, mRNA-1273, AZD1222, CoronaVac, Sinopharm, Gam-COVID-Vac, JNJ-78436735, CVnCoV, NVX-CoV2373, BBV152
Masaryk University
Adverse Reaction to Vaccine, COVID19 Vaccine
12/25
12/26

Download Options